Profile data is unavailable for this security.
About the company
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.
- Revenue in USD (TTM)522.75m
- Net income in USD-558.99m
- Incorporated2011
- Employees1.28k
- LocationUltragenyx Pharmaceutical Inc60 Leveroni CtNOVATO 94949-5746United StatesUSA
- Phone+1 (415) 483-8800
- Fax+1 (415) 483-8810
- Websitehttps://www.ultragenyx.com/